PMGC Holdings notifies availability of NorthStrive Biosciences Phase III AI-driven drug discovery update

PMGC Holdings Inc.

PMGC Holdings Inc.

ELAB

0.00
  • PMGC published a press release on NorthStrive Biosciences’ Phase III AI drug-discovery results with Yuva Biosciences targeting muscle metabolism.
  • Four AI-selected small molecules boosted ANT1 expression in primary human skeletal muscle cells; top responses reached 50%.
  • Program moves to confirmatory testing in a more mature skeletal muscle model to support further development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.